P/E ratio for Dr. Reddy's (RDY)
P/E ratio as of April 2024 (TTM): 19.1
According to Dr. Reddy's's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.1107. At the end of 2022 the company had a P/E ratio of 19.1.
P/E ratio history for Dr. Reddy's from 2002 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 19.1 | -33.03% |
| 2021 | 28.5 | -31.57% |
| 2020 | 41.7 | 44.76% |
| 2019 | 28.8 | 15.87% |
| 2018 | 24.8 | -38.85% |
| 2017 | 40.6 | -22.84% |
| 2016 | 52.6 | 151.93% |
| 2015 | 20.9 | -13.41% |
| 2014 | 24.1 | 29.94% |
| 2013 | 18.6 | -16.03% |
| 2012 | 22.1 | 30.15% |
| 2011 | 17.0 | -43.59% |
| 2010 | 30.1 | -253.81% |
| 2009 | -19.6 | -245.48% |
| 2008 | 13.5 | -38.1% |
| 2007 | 21.7 | -0.76% |
| 2006 | 21.9 | -58.01% |
| 2005 | 52.2 | -36.77% |
| 2004 | 82.5 | 100.2% |
| 2003 | 41.2 | 30.8% |
| 2002 | 31.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 26.3 | 37.60% | 🇨🇭 Switzerland |
 Pfizer PFE | 14.1 | -26.10% | 🇺🇸 USA |
 Sanofi SNY | 14.7 | -23.31% | 🇫🇷 France |
 GlaxoSmithKline GSK | 11.7 | -38.92% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | -6.51 | -134.04% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.